Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation

Description

To identify diagnostic and prognostic biomarker signatures of recovery versus having persisting high-impact chronic pain and functional disability in adults with Chronic Musculoskeletal Pain.

Conditions

Chronic Musculoskeletal Pain, Pain, Pain, Chronic, Joint Pain

Study Overview

Study Details

Study overview

To identify diagnostic and prognostic biomarker signatures of recovery versus having persisting high-impact chronic pain and functional disability in adults with Chronic Musculoskeletal Pain.

Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation

Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation

Condition
Chronic Musculoskeletal Pain
Intervention / Treatment

-

Contacts and Locations

Palo Alto

Stanford University, Palo Alto, California, United States, 94304

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 1)
  • * 1) Chronic musculoskeletal pain (MSP) explained by inflammatory disease (e.g., rheumatoid arthritis, lupus) or CP with a primary diagnosis other than chronic MSP (e.g., neuropathic pain), (2) significant cognitive impairment, (3) MRI contraindication, (4) medical or psychiatric problems interfering with the study, (5) current medicolegal factors (e.g., open disability claim), (6) plans for surgery during the study, (7) pregnancy and (8) Children under the age of 18 will not be included in the study.

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Sean Mackey, MD, PhD., PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2027-12-31